Currently, there are 542.90M common shares owned by the public and among those 542.34M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -0.46% and 10.10% over the past three months. MMM shares are trading 12.99% year to date (YTD), with the 12-month market performance up to 89.38% higher. It has a 12-month low price of $75.65 and touched a high of $156.35 over the same period. MMM has an average intraday trading volume of 3.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.43%, 2.21%, and 15.13% respectively.
Institutional ownership of 3M Co (NYSE: MMM) shares accounts for 68.68% of the company’s 542.90M shares outstanding.
It has a market capitalization of $79.19B and a beta (3y monthly) value of 0.99. The stock’s trailing 12-month PE ratio is 19.32, while the earnings-per-share (ttm) stands at $7.55. The company has a PEG of 2.27 and a Quick Ratio of 1.08 with the debt-to-equity ratio at 3.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.57% over the week and 2.17% over the month.
Earnings per share for the fiscal year are expected to increase by 6.95%, and 9.03% over the next financial year. EPS should grow at an annualized rate of 8.52% over the next five years, compared to -0.67% over the past 5-year period.
Looking at the support for the MMM, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on January 22, 2025, with the firm’s price target at $140-$170. UBS coverage for the 3M Co (MMM) stock in a research note released on November 13, 2024 offered a Buy rating with a price target of $184. Melius was of a view on October 22, 2024 that the stock is Buy, while Morgan Stanley gave the stock Underweight rating on September 06, 2024, issuing a price target of $125. Argus on their part issued Buy rating on July 30, 2024.
